Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
British Journal of Cancer|January 14, 2015
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expressionM Zhu, R Tang, S Doshi, et al.
Cancer Treatment Reports|January 1, 1987
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trialS M Longnecker, R C Donehower, A E Cates, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
The effects of food and divided dosing on the bioavailability of oral vinorelbineE K Rowinsky, V S Lucas, A L Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Cancer Research|January 15, 1994
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeksE K Rowinsky, L B Grochow, D S Ettinger, et al.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Cancer Research|November 1, 1991
Phase I and pharmacokinetic study of hepsulfam (NSC 329680)C B Hendricks, L B Grochow, E K Rowinsky, et al.
Cancer Investigation|August 3, 2000
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerE C Dees, S O'Reilly, S N Goodman, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|January 14, 2015
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expressionM Zhu, R Tang, S Doshi, et al.
Cancer Treatment Reports|January 1, 1987
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trialS M Longnecker, R C Donehower, A E Cates, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
The effects of food and divided dosing on the bioavailability of oral vinorelbineE K Rowinsky, V S Lucas, A L Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Cancer Research|January 15, 1994
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeksE K Rowinsky, L B Grochow, D S Ettinger, et al.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Cancer Research|November 1, 1991
Phase I and pharmacokinetic study of hepsulfam (NSC 329680)C B Hendricks, L B Grochow, E K Rowinsky, et al.
Cancer Investigation|August 3, 2000
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerE C Dees, S O'Reilly, S N Goodman, et al.
Pageof 13